Adjuvant chemotherapy in biliary tract cancer patients: A systematic review and meta-analysis of randomized controlled trials

被引：5

作者：

Caparica, Rafael ^{[1
,2
]}

Bruzzone, Marco ^{[3
]}

El Hachem, Georges ^{[4
]}

Ceppi, Marcello ^{[3
]}

Lambertini, Matteo ^{[5
,6
]}

Glasberg, Joao ^{[7
]}

de Azambuja, Evandro ^{[1
,2
]}

Van Laethem, Jean-Luc ^{[8
]}

Hendlisz, Alain ^{[1
,2
]}

机构：

[1] Inst Jules Bordet, Dept Med Oncol, Brussels, Belgium

[2] Univ Libre Bruxelles, Brussels, Belgium

[3] IRCCS Osped Policlin San Martino, Clin Epidemiol Unit, Genoa, Italy

[4] St George Hosp Univ, Dept Hematol & Med Oncol, Med Ctr, Beirut, Lebanon

[5] IRCCS Osped Policlin San Martino, Dept Med Oncol, UOC Clin Oncol Med, Genoa, Italy

[6] Univ Genoa, Sch Med, Dept Internal Med & Med Specialties DiMI, Genoa, Italy

[7] Univ Sao Paulo, Inst Canc Estado Sao Paulo, Dept Med Oncol, Sao Paulo, Brazil

[8] Univ Libre Bruxelles, Dept Gastroenterol Hepatol & Digest Oncol, Hop Erasme, Brussels, Belgium

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2020年 / 149卷

关键词：

Biliary tract cancer; Adjuvant therapy; Chemotherapy; Survival; Relapse; ERLOTINIB PLUS GEMCITABINE; ADVANCED PANCREATIC-CANCER; CHOLANGIOCARCINOMA;

D O I：

10.1016/j.critrevonc.2020.102940

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The role of adjuvant chemotherapy in biliary tract cancer is controversial. We performed a systematic review and meta-analysis to assess the effect of adjuvant chemotherapy in biliary tract cancer patients. Methods: A literature search was performed to identify randomized controlled trials (RCTs) comparing adjuvant chemotherapy versus observation, and a pooled analysis was conducted using the random-effect model. Results: Three RCTs (N = 866) were included. No difference was observed between chemotherapy and observation in terms of OS (HR 0.91; 95 %CI, 0.75-1.09; p = 0.295), whereas a significant improvement in RFS was shown (HR 0.83; 95 %CI, 0.69-0.99; p = 0.040). No subgroup that benefited most from adjuvant chemotherapy was identified, although a trend was observed in N+ patients (HR 0.83; 95 %CI, 0.65-1.08; p = 0.165). Discussion: Adjuvant chemotherapy yields a significant RFS benefit in biliary tract cancer patients and should be considered for those who are able to tolerate additional treatment after surgery.

引用

页数：9

共 25 条

[1] Gemcitabine-based chemotherapy for advanced biliary tract carcinomas [J].

Abdel-Rahman, Omar ;

Elsayed, Zeinab ;

Elhalawani, Hesham .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (04)

[2] Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer [J].

Ebata, T. ;

Hirano, S. ;

Konishi, M. ;

Uesaka, K. ;

Tsuchiya, Y. ;

Ohtsuka, M. ;

Kaneoka, Y. ;

Yamamoto, M. ;

Ambo, Y. ;

Shimizu, Y. ;

Ozawa, F. ;

Fukutomi, A. ;

Ando, M. ;

Nimura, Y. ;

Nagino, M. .

BRITISH JOURNAL OF SURGERY, 2018, 105 (03) :192-202

[3] Current Status on Cholangiocarcinoma and Gallbladder Cancer [J].

Ebata, Tomoki ;

Ercolani, Giorgio ;

Alvaro, Domenico ;

Ribero, Dario ;

Di Tommaso, Luca ;

Valle, Juan W. .

LIVER CANCER, 2017, 6 (01) :59-65

[4] Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study [J].

Edeline, Julien ;

Benabdelghani, Meher ;

Bertaut, Aurelie ;

Watelet, Jerome ;

Hammel, Pascal ;

Joly, Jean-Paul ;

Boudjema, Karim ;

Fartoux, Laetitia ;

Bouhier-Leporrier, Karine ;

Jouve, Jean-Louis ;

Faroux, Roger ;

Guerin-Meyer, Veronique ;

Kurtz, Jean-Emmanuel ;

Assenat, Eric ;

Seitz, Jean-Francois ;

Baumgaertner, Isabelle ;

Tougeron, David ;

de la Fouchardiere, Christelle ;

Lombard-Bohas, Catherine ;

Boucher, Eveline ;

Stanbury, Trevor ;

Louvet, Christophe ;

Malka, David ;

Phelip, Jean-Marc .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08) :658-+

[5] Burden of Digestive Diseases in the United States Part III: Liver, Biliary Tract, and Pancreas [J].

Everhart, James E. ;

Ruhl, Constance E. .

GASTROENTEROLOGY, 2009, 136 (04) :1134-1144

[6] Biliary tract cancer: current challenges and future prospects [J].

Ghidini, Michele ;

Pizzo, Claudio ;

Botticelli, Andrea ;

Hahne, Jens Claus ;

Passalacqua, Rodolfo ;

Tomasello, Gianluca ;

Petrelli, Fausto .

CANCER MANAGEMENT AND RESEARCH, 2019, 11 :379-388

[7] Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis [J].

Ghidini, Michele ;

Tomasello, Gianluca ;

Botticelli, Andrea ;

Barni, Sandro ;

Zabbialini, Giampietro ;

Seghezzi, Silvia ;

Passalacqua, Rodolfo ;

Braconi, Chiara ;

Petrelli, Fausto .

HPB, 2017, 19 (09) :741-748

[8] EVIDENCE-BASED MEDICINE - A NEW APPROACH TO TEACHING THE PRACTICE OF MEDICINE [J].

GUYATT, G .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (17) :2420-2425

[9] The Cochrane Collaboration's tool for assessing risk of bias in randomised trials [J].

Higgins, Julian P. T. ;

Altman, Douglas G. ;

Gotzsche, Peter C. ;

Jueni, Peter ;

Moher, David ;

Oxman, Andrew D. ;

Savovic, Jelena ;

Schulz, Kenneth F. ;

Weeks, Laura ;

Sterne, Jonathan A. C. .

BMJ-BRITISH MEDICAL JOURNAL, 2011, 343

[10] Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis [J].

Horgan, Anne M. ;

Amir, Eitan ;

Walter, Thomas ;

Knox, Jennifer J. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) :1934-1940

← 1 2 3 →